Covaris Introduces a High Performance Extraction and Dissolution System for Proteomics and Metabolic Profiling

WOBURN, MA—November 26, 2001—Covaris, Inc. announced today an innovation in sample preparation for proteomics; the science of the protein content of whole cells or tissues. The proteomics industry is expected to become at least as significant as the genomics market and predicted to grow to $2.5 billion by 2005. The new system is called the E100. This is a dedicated instrument using Covaris’ enabling technologies for High-Throughput Screening. “Researchers at biotechnology, genomics and pharmaceutical companies using our proprietary extraction and dissolution technologies can dramatically improve the throughput speed, increase recoveries and reduce the variability of results in numerous types of biological samples” said James Laugharn, President of Covaris. Furthermore Mr. Laugharn said that “The E100 is an ideal sample preparation station for laboratories using high-throughput protein factory technologies. After all, in high-throughput biology, metabolic profile variations should come from the samples, not from one of the processes to prepare the samples.”

As both analytical technologies become more sensitive and robotic controls allow higher sample processing throughput, demands on quality sample preparation become more important. The Covaris E100 instrument may become an industry standard to provide a novel, mechanical control of a currently uncontrolled process as High-Throughput applications that require controlled extracting, mixing, dissolving or resuspending can be standardized with the Covaris technology.

The E100 is a multi-use sample preparation system. Some specific applications of the E100 are: increasing plant and animal tissue metabolite extraction recoveries for LC/MS direct analysis, improving solubilization of protein complexes and aggregates for 2-D gel electrophoresis, and accelerating reagent dissolution. A key advantage of the technology is that the first and last samples receive identical process energy to ensure standardized, reproducible results.

About Covaris:
Covaris, Inc. is a privately held company founded in 1999 to develop instrument systems based on its proprietary, patent-pending, biophysical technology platform. The technology is based on focused acoustic energy and applications of shock wave physics for advanced and high-throughput applications in biology and medicine.

Contact:
Covaris, Inc.
14 Gill Street, Unit H
Woburn, Massachusetts
USA 01801-1721
Tel: +1 781-932-3959
Fax: +1 781-932-8705
e-mail: info@covaris.com

Covaris Technology Improves BioChip Performance

WOBURN, MA—January 4, 2001—Covaris, Inc. announces an innovation in microarray hybridization. The microarray industry is predicted to grow to $3 billion by 2003. This is a new application using Covaris’ enabling technology platform for High-Throughput biology. Covaris’ proprietary shock wave technology can dramatically improve the throughput speed, increase sensitivity and reduce the variability of results in all types of biochips.

Covaris president James Laugharn said that “researchers at biotechnology, genomics and pharmaceutical companies using biochips to speed up drug delivery will find this technology indispensable for achieving the best results in the shortest timeframes.” Furthermore, Laugharn said, “as biochips enter the diagnostic market, the Covaris technology will be helpful in meeting the tight requirements for FDA approval of new assays.”

Covaris, Inc. has invented a novel technique to actively control and mix fluids in microfluidic devices, such as microarrays. The technology is based upon proprietary acoustic field control processes and custom instrumentation developed by the staff at Covaris. These processes are scalable from milliliter to microliter to nanoliter volumes. In addition, the processes are also adaptable to lab-on-a-chip systems.

At present, there are three major steps in the processing of DNA microarrays: spotting, hybridizing, and scanning. Although there have been exciting advances in the spotting (production) and the scanning (analysis) areas, there have been few advances in the actual hybridization (reaction process). In fact current gene expression microarray hybridizations typically take between 16 and 20 hours.

Some of the concerns in preforming microarrays, such as for gene expression profiling, are the tendency of the sample to reanneal with homologous sequences and the tendency to form intramolecular duplexes. Both of these effectively lower the potential sensitivity of the systems. Another concern is that techniques to accelerate the overall hybridization rate in microarray formats are based on increasing the effective diffusion of the target (solution phase) through controlled mixing. This is difficult in small scales. The Covaris process enables both active control and mixing of these small volumes.

Benefits of the Covaris hybridization process on biochip systems are: 1) the overall sensitivity of the assay is increased by using acoustic field control for target denaturation of both intramolecular duplexes and homologous, double stranded sequences, 2) the overall hybridization rate is accelerated by actively controlling the efficiency of the collisions between target (solution phase) and the probe (solid phase) using acoustic field control for fluid exchange, and 3) the process can used in production applications to improve uniformity across an array thereby reducing background and improving signal to noise ratio.

As the microarray technology develops in the next few years from a research to a clinical tool, the requirements for improved precision and accuracy will become important. The Covaris hybridization instrument may become an industry standard to provide active control of a currently uncontrolled process.

High-Throughput applications that require controlled mixing, dissolving or resuspension can be standardized with the Covaris technology. The technology applies computer-controlled shock wave physics to life sciences. These shock waves can penetrate closed vessels and then converge in the mixing zone. The system can accommodate various types and sizes of microarrays.

Covaris, Inc. is a privately held company founded in 1999 to develop instrument systems based on its proprietary biophysical platform.

About Covaris:
Covaris, Inc. is a privately held company founded in 1999 to develop instrument systems based on its proprietary, patent-pending, biophysical technology platform. The technology is based on focused acoustic energy and applications of shock wave physics for advanced and high-throughput applications in biology and medicine.

Contact:
Covaris, Inc.
14 Gill Street, Unit H
Woburn, Massachusetts
USA 01801-1721
Tel: +1 781-932-3959
Fax: +1 781-932-8705
e-mail: info@covaris.com

Covaris Introduces a High-Throughput, High-Precision Mixing System

WOBURN, MA—March 6, 2000—Covaris, Inc. announces its innovative High-Throughput sample mixing technique. This is a new application of Covaris¹ enabling technology platform for High-Throughput biology research.

The exCELLerator™system enables non-contact mixing for automated sample preparation and processing. High-Throughput applications that require controlled mixing, dissolving or resuspension can be standardized with this technology. The Covaris Process applies computer-controlled shock wave physics to life sciences. These shock waves can penetrate closed vessels and then converge in a mixing zone. This technology can work with completely closed vessels for enhanced safety of users. Since mixing occurs without the need of stirring implements and in closed vessels, sample-to-sample cross contamination is eliminated. The process may also be used in conjunction with, and to improve the efficiencies of resin, bead, and paramagnetic particle-based mixing processes.

The exCELLerator is designed to accommodate a variety of sample vessels, including tubes, multi-well plates, and microarrays in a random access, individually addressable format. The instrument can be used to mix a single well or a whole multi-well plate in batch mode. Depending on the sample volume, the Covaris system will mix a multi-well plate of samples in less than one minute without operator assistance. For example, with a 1 microliter sample volume the processing time may be less than a millisecond. The Covaris system is amenable to both cell-based processes and biochemical assays.

The exCELLerator system is the leading edge of High-Throughput sample processing technology. It is designed for state-of-the art laboratories that need a reproducible, robust sample mixing process in fields such as toxicology, functional genomics, target validation and proteomics.

Covaris, Inc. is a privately held company founded in 1999 to develop instrument systems based on its proprietary biophysical technology platform. ExCELLerator systems are being installed in High-Throughput laboratories, however, this technology is still open for licensing in specific fields of use. The system can be configured as either a stand-alone, bench-top apparatus or as a module for a robotic-based laboratory.

About Covaris:
Covaris, Inc. is a privately held company founded in 1999 to develop instrument systems based on its proprietary, patent-pending, biophysical technology platform. The technology is based on focused acoustic energy and applications of shock wave physics for advanced and high-throughput applications in biology and medicine.

Contact:
Covaris, Inc.
14 Gill Street, Unit H
Woburn, Massachusetts
USA 01801-1721
Tel: +1 781-932-3959
Fax: +1 781-932-8705
e-mail: info@covaris.com

Computer Controlled Shock Wave Instrument for High-Throughput Sample Preparation

WOBURN, MA—February 2, 2000—Covaris, Inc. announces today its new instrument system for High-Throughput biology research.

The exCELLerator™ E1 system from Covaris standardizes cellular lysis and tissue disruption for automated sample preparation. For the first time, life scientists have a system that can reproducibly deliver mechanical energy to a sample. This is achieved through the precisely controlled generation and pinpoint delivery of shock waves. These shock waves can penetrate closed vessels; this provides sterile handling and enhanced safety for users.

The exCELLerator is designed for use with a variety of sample holders, including tubes and multi-well plates for High-Throughput applications. The system will process a multi-well plate of tissue samples in less than five minutes without operator assistance. With a wide range of user specified temperatures and no need to add lytic chemicals, this powerful acoustic disrupter is gentler to the target molecules, such as nucleic acids and proteins, that researchers need to extract than the current manual or chemical methods. A large variety of samples can be treated including bone, liver, and plant tissues as well as microbes.

The exCELLerator system is the leading edge of High-Throughput sample processing technology. It is designed for researchers who need the greatest precision in sample preparation in fields such as toxicology, functional genomics, target validation, and proteomics. The exCELLerator system is especially valuable for high volume, hard tissue sample preparation where preserving the integrity of extracted molecules is important. The system is currently available either as a stand-alone, bench-top apparatus or as a module for a robotics-based laboratory.

About Covaris:
Covaris, Inc. is a privately held company founded in 1999 to develop instrument systems based on its proprietary, patent-pending, biophysical technology platform. The technology is based on focused acoustic energy and applications of shock wave physics for advanced and high-throughput applications in biology and medicine.

Contact:
Covaris, Inc.
14 Gill Street, Unit H
Woburn, Massachusetts
USA 01801-1721
Tel: +1 781-932-3959
Fax: +1 781-932-8705
e-mail: info@covaris.com